Prevalence of scleroderma in Spain: an approach for estimating rare disease prevalence using a disease model

被引:8
作者
Villaverde-Hueso, A. [1 ,2 ]
de la Paz, M. Posada [1 ,2 ]
Martin-Arribas, M. C. [1 ,2 ]
Sanchez-Valle, E. [1 ,2 ]
Ramirez-Gonzalez, A. [1 ,2 ]
Biairdi, P. [3 ,4 ]
机构
[1] Inst Salud Carlos III, Res Inst Rare Dis, Madrid 28029, Spain
[2] CIBERER, Madrid, Spain
[3] Univ Pavia, Consorzio Valutaz Biol & Farmacol, I-27100 Pavia, Italy
[4] S Maugeri Fdn, Pavia, Italy
关键词
scleroderma; rare diseases; prevalence; orphan drugs; epidemiology;
D O I
10.1002/pds.1660
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To estimate scleroderma prevalence in Spain. Methods As no data were available for Spain we used reported scleroderma incidence (Silman's study on UK and Alamanos' on Greece), scleroderma cause-specific mortality, obtained through the National Institute of Statistics (codes included in M34 of the International Classification of Diseases, 10th revision) in Spain and remission data. Estimates were applied to the Spanish population and to all-cause mortality for 2004, broken down by age group and gender. Estimators were assumed to follow a Poisson distribution. DisMod-II software was used for this purpose. Results Estimated prevalence was 0.23 and 0.71 cases per 10 000 people for men and women, respectively, based on UK incidence, and 0,28 and 2.58 cases per 10 000 people, respectively, based on Greek incidence. Estimated age at disease onset ranged from 50 to 58 years among men and from 52 to 55 among women, according to UK and Greek data, respectively. Mean duration of the disease was estimated to be in the range of 17-20 years for men and 19-20 for women. Conclusions DisMod-II is useful for obtaining, modelling and confirming variability ranges of prevalence found in literature. It also provides information for orphan drug designation and for supporting public health decisions regarding rare diseases. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:1100 / 1107
页数:8
相关论文
共 29 条
[1]   Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002 [J].
Alamanos, Y ;
Tsifetaki, N ;
Voulgari, PV ;
Siozos, C ;
Tsamandouraki, K ;
Alexiou, GA ;
Drosos, AA .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (05) :714-720
[2]   A study of the prevalence of systemic sclerosis in northeast England [J].
Allcock, RJ ;
Forrest, I ;
Corris, PA ;
Crook, PR ;
Griffiths, ID .
RHEUMATOLOGY, 2004, 43 (05) :596-602
[3]  
[Anonymous], INT STAT CLASS DIS R
[4]  
[Anonymous], 1996, GLOBAL BURDEN DIS IN
[5]   Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma - Association with an Amerindian HLA haplotype [J].
Arnett, FC ;
Howard, RF ;
Tan, FM ;
Moulds, JM ;
Bias, WB ;
Durban, E ;
Cameron, HD ;
Paxton, G ;
Hodge, TJ ;
Weathers, PE ;
Reveille, JD .
ARTHRITIS AND RHEUMATISM, 1996, 39 (08) :1362-1370
[6]  
Barendregt J, DISMOD II
[7]   A generic model for the assessment of disease epidemiology: The computational basis of DisMod II [J].
Jan J Barendregt ;
Gerrit J van Oortmarssen ;
Theo Vos ;
Christopher JL Murray .
Population Health Metrics, 1 (1)
[8]   Consistency of epidemiologic estimates [J].
Barendregt, JJ ;
Ott, A .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2005, 20 (10) :827-832
[9]  
*COMP, 2003, EMEACOMP7402
[10]   Burden of disease related to Parkinson's disease in Spain in the year 2000 [J].
Cubo, E ;
Alvarez, E ;
Morant, C ;
Cuesta, JD ;
Martín, PM ;
Génova, R ;
Freire, JM .
MOVEMENT DISORDERS, 2005, 20 (11) :1481-1487